{"id":1,"date":"2022-02-04T06:41:48","date_gmt":"2022-02-04T05:41:48","guid":{"rendered":"https:\/\/vascular.hu\/holding\/?p=1"},"modified":"2022-03-23T12:26:48","modified_gmt":"2022-03-23T11:26:48","slug":"new-member-of-the-team","status":"publish","type":"post","link":"https:\/\/vascular.hu\/holding\/new-member-of-the-team\/","title":{"rendered":"New member to the team"},"content":{"rendered":"\n<div class=\"wp-block-image\"><figure class=\"aligncenter size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"520\" height=\"670\" src=\"https:\/\/vascular.hu\/holding\/wp-content\/uploads\/2022\/02\/megyerimarton.png\" alt=\"facebook\" class=\"wp-image-16306\" srcset=\"https:\/\/vascular.hu\/holding\/wp-content\/uploads\/2022\/02\/megyerimarton.png 520w, https:\/\/vascular.hu\/holding\/wp-content\/uploads\/2022\/02\/megyerimarton-233x300.png 233w\" sizes=\"(max-width: 520px) 100vw, 520px\" \/><\/figure><\/div>\n\n\n\n<p class=\"wp-block-paragraph\">We are excited to announce that M\u00e1rton Megyeri has joined to the team as Head of CMC Development on the 1st of December 2021. He is going to bring a chemistry manufacturing and controls (CMC) and regulatory perspective to the team by managing late-stage research projects of the portfolio. Previously, by leading a team that provided integrated scientific and strategic support for the CMC biosimilar development he completed successful INDs and other regulatory submissions to FDA and EMA. M\u00e1rton is a bioengineer by training, holds a PhD in structural biochemistry and protein science. He was a postdoc in the Weizmann Institute of Science and held various roles within the biotech industry pipeline. With 9+ years of bio-pharmaceutical experience and 15+ years of academic track record and a passion for science he is going to complete the team\u2019s expertise to cover the full spectra of biologics development.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>We are excited to announce that M\u00e1rton Megyeri has joined to the team as Head of CMC Development on the 1st of December 2021. He is going to bring a chemistry manufacturing and controls (CMC) and regulatory perspective to the team by managing late-stage research projects of the portfolio. Previously, by leading a team that [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[81,42],"tags":[],"class_list":["post-1","post","type-post","status-publish","format-standard","hentry","category-news","category-vascular-reserach-group"],"_links":{"self":[{"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/posts\/1","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/comments?post=1"}],"version-history":[{"count":2,"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/posts\/1\/revisions"}],"predecessor-version":[{"id":16743,"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/posts\/1\/revisions\/16743"}],"wp:attachment":[{"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/media?parent=1"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/categories?post=1"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/tags?post=1"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}